Industry context
IntraCellular Therapies [ITCI]
Last Updated 2 Apr 2025 @ 16:00 (Exchange is open)
Last: $131.87
0.00%
2.86 (↑)
GaG Algo Score™
v1.0
Short
2.86 (↑)
Medium
4.71 (↑)
Long
4.44 (↑)
Line
Pivot Data
Pivot Statistics
Insufficient pivot data for statistics.
Next Pivot Prediction Last: $131.87
Unable to generate prediction based on available data.
IntraCellular Therapies flat yesterday.
IntraCellular Therapies (ITCI) stock price remained flat on Wednesday after the stock unchanged $0 (0.00%) from the previous session on extremely light volume. The stock moved in line with the rising NASDAQ that gained 0.22%. A total of 0 stocks were traded yesterday, valued at $0.00, 16.06M shares less than the previous day (16 063 000 shares traded). This is below the average volume for the stock at 2.93M shares traded per day.
IntraCellular Therapies signals
The last upturn is pushing the stock into overbought territory (RSI above 70) with a current RSI of 84.55, which traditionally suggests the stock may be overvalued in the short term. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (40%), medium- (40%), and long-term (40%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
IntraCellular Therapies Support & Resistance Levels
The stock is approaching the closest resistance level at $131.90. approximately $0.0300 (0.02%) away. Consolidating near resistance. Breaking above this level could signal further upside where next resistance level will be found at $. On a fall back there will be support at $127.2 The dis das resistance s1127.2 -
IntraCellular Therapies Evaluation
- Short score: 2.86
- Medium score: 4.71
- Long score: 4.44
Ownership flow
GetAGraph InsiderPower
Transactions
134
Buy power
644 837
Sell power
2 793 446
2025-04-02
Salas Eduardo Rene
Sell
2025-04-02
Salas Eduardo Rene
Sell
2025-04-02
Salas Eduardo Rene
Sell
2025-04-02
Salas Eduardo Rene
Sell
2025-04-02
Salas Eduardo Rene
Sell
Positioning pressure
Short interest pressure
Short interest
2.43%
Of outstanding shares
Short float
2.47%
Of tradable float
Days to cover
1.840
Short interest divided by average volume
Squeeze probability
-
-3.10% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2025-03-31Earnings quality
Earnings history
Reported quarters
8
EPS beats
7
EPS misses
1
Avg. surprise
22.15%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-10-28 | - | - | - | - |
| Q2/2025 | 2025-08-05 | - | - | - | - |
| Q1/2025 | 2025-05-05 | - | - | - | - |
| Q4/2024 | 2025-02-27 | - | $-0.0500 | - | - |
| Q3/2024 | 2024-10-30 | $-0.250 | $-0.180 | -38.89% | 175.16M |
| Q2/2024 | 2024-08-07 | $-0.160 | $-0.180 | 11.11% | 161.39M |
| Q4/2023 | 2024-02-22 | $-0.300 | $-0.440 | 31.82% | 131.51M |
| Q3/2023 | 2023-11-02 | $-0.250 | $-0.590 | 57.63% | 125.81M |
Analyst view
Analyst targets
Consensus
$98.50
Median
$101.50
Low
$70.00
High
$132.00
Recent target updates
News flow
Latest company news
Market coverage
globenewswire.com Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update May 1, 2025 businesswire.com INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI Feb 25, 2025 businesswire.com ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders Feb 24, 2025 zacks.com ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales Feb 24, 2025Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers Specialty Generic
Currency
USD
IntraCellular Therapies Inc a biopharmaceutical company develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States The company offers CAPLYTA for the treatment of schizophrenia in adults It is also involved in developing lumateperone which is in Phase III clinical trial for the treatment of bipolar depression as well as to treat autism spectrum disorder and in additional neuropsychiatric indications such as sleep disorders associated with neuropsychiatric and neurological disorders In addition the company is developing Lenrispodun ITI214 for the treatment of Parkinsons disease and heart failure ITI1284ODTSL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia and ITI333 for substance use disorders pain and psychiatric comorbidities including depression and anxiety IntraCellular Therapies Inc was founded in 2002 and is headquartered in New York New York
Navigation